X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

AMR Is The Main Focus of New Research Consortium In World

Content Team by Content Team
2nd May 2023
in News, Research & Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Global research consortium is being set up to address the international impact of antimicrobial resistance (AMR). Significantly, the Centres for Antimicrobial Optimisation Network- CAMO-Net brings together research team from South Africa’s University of Cape Town, the University of Liverpool as well as Imperial College, London, the Ugandan Infectious Disease Institute, as well as the faculty of medicine at Brazil’s University of Sao Paulo.

CAMO-Net looks to optimise antimicrobial usage in humans by way of a sustainable global research spectrum that is developed across low, middle, and high resource settings throughout the rural as well as urban landscape. The University of Liverpool’s Professor Alison Holmes and Imperial College London in the UK declared that not only is this network going to provide a one-off unique opportunity so as to advance the multidisciplinary research to improve as well as sustain access to antimicrobial treatments that are effective and also address AMR, it has also shared the global learning embedded within it and also goes on to represent a significant commitment when it comes to research models that are more equitable.

Researchers will work towards building knowledge when it comes to optimal antibiotic usage, enhanced access to treatment that’s effective, and better prevention and treatment of bacterial infections. This initiative will help enhance clinical decision-making when it comes to antimicrobial usage and also help prescribers, policymakers, and users with practises and guidelines.

The Executive Director, Infectious Disease Institute in Uganda, called the country’s engagement in the CAMO-Net pathbreaking and an opportunity to generate research so as to help in overcoming AMR across the region.

The consortium’s main operations will be spread across regions that have a very high burden of drug-resistant infections while also making use of a multi-sectoral and system-based approach to enhancing antimicrobial usage. CAMO-Net is going to work with its collaborators in order to research how to actionably enhance antimicrobial use in humans via three inter-linked themes that are identified via the Wellcome-commisioned roadmap.

The four sites constitute national hubs that are responsible for driving the research and spearheading the global network. Each hub happens to have specific as well as complementary research expertise and shall go on to receive exclusive funding with awards, thereby linking directly with that of the other three countries.

The objective is to improve research equity by ensuring local leadership and encouraging joint ownership within the programmes. These constituents happen to be forming the core value of the consortium in sync with knowledge mobilisation, mutually beneficial cross-regional learning, and output sharing. The network looks to build a complete contextual understanding when it comes to situational data across each national hub so as to pinpoint opportunities and also address challenges as well as gaps.

CAMO-Net will also include 3 shadow national sites that will go on to participate in network activities and also build a project that happens to be a part of a larger CAMO-Net programme.

Previous Post

Gene Silencing Alzheimers Drug, A World First, Shows Promise

Next Post

EU Drug Manufacturing Law Changes Disappoint Manufacturers

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

EU Drug Manufacturing Law Changes Disappoint Manufacturers

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In